William Meury
Known title: Chief Executive OfficerCIK: 0001536778
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
SNDX Drops After Axatilimab IPF Trial Misses Endpoint. Syndax Pharmaceuticals stock fell sharply after topline results from the MAXPIRe Phase 2 trial showed axatilimab did not meet its primary endpoint in idiopathic pulmonary fibrosis. The negative data triggered a significant selloff, with the stock dropping as much as 16% in after-hours trading. While some analysts maintain price targets, the trial outcome has raised questions about the drug's potential in this indication.
Transaction History
| INCY | ▲ Buy | Grant | 26,807 | $0 | 7/16/2026 | View on chart |
| INCY | ▼ Sell | Tax Withholding | 4,779 | $558K | 7/2/2026 | View on chart |
| INCY | ▲ Buy | Option Exercise | 125,000 | $0 | 4/15/2026 | View on chart |
| INCY | ▲ Buy | Grant | 36,101 | $0 | 7/2/2025 | View on chart |
| SNDX | ▲ Buy | Grant | 25,000 | $0 | 2/5/2025 | View on chart |
| SNDX | ▲ Buy | Grant | 17,000 | $0 | 2/7/2024 | View on chart |
| SNDX | ▲ Buy | Option Exercise | 35,000 | $249K | 8/2/2023 | View on chart |
| SNDX | ▼ Sell | Open Market | 35,000 | $716K | 8/2/2023 | View on chart |
| SNDX | ▲ Buy | Option Exercise | 24,000 | $189K | 8/2/2023 | View on chart |
| SNDX | ▼ Sell | Open Market | 24,000 | $491K | 8/2/2023 | View on chart |
| SNDX | ▲ Buy | Option Exercise | 24,000 | $227K | 8/2/2023 | View on chart |
| SNDX | ▼ Sell | Open Market | 24,000 | $491K | 8/2/2023 | View on chart |
| SNDX | ▲ Buy | Grant | 16,000 | $0 | 2/2/2023 | View on chart |
| SNDX | ▲ Buy | Grant | 16,000 | $0 | 2/2/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Incyte receives mixed analyst updates with price target changes
Incyte saw two recent analyst actions with differing views. Truist Securities raised its price target to $115 while maintaining a Hold rating. Conversely, HC Wainwright reiterated a Buy rating and kept its target at $152. These moves reflect a wide range of expectations among analysts for the stock's future performance.
Incyte receives mixed analyst updates with price target changes. Incyte saw two recent analyst actions with differing views. Truist Securities raised its price target to $115 while maintaining a Hold rating. Conversely, HC Wainwright reiterated a Buy rating and kept its target at $152. These moves reflect a wide range of expectations among analysts for the stock's future performance.